Our previous data demonstrated that metformin increases the levels of conjugated BAs in the gut by reducing the abundance of Bacteroides fragilis species to antagonize intestinal farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) signaling, thereby improving insulin sensitivity in T2DM patients [17]. This evidence concerns the gene NR1H4 and type 2 diabetes mellitus.